# Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

> **NCT06321341** · PHASE4 · RECRUITING · sponsor: **Valenta Pharm JSC** · enrollment: 160 (estimated)

## Conditions studied

- Vertigo
- Autonomic Dysfunction

## Interventions

- **DRUG:** Vespireit
- **DRUG:** Arlevert

## Key facts

- **NCT ID:** NCT06321341
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-24
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06321341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06321341, "Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06321341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*